Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis-Reference-Cited by-同舟云学术

Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis

Published:2016-08-31 Issue:8 Volume:11 Page:e0160148
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ma Xuelei,Wang Xiaoshan,Huang Jingwen,Chen Yingtai,Zhang Jing,Zhang Binglan,Shi Changle,Liu Lei

Funder

National Natural Science Foundation of China, Beijing, China

Research Award Fund for New Young Teachers in Higher Education Institutions, China

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference54 articles.

1. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses;T Brodowicz;Br J Cancer,2014

2. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial;JC Boughey;Ann Surg,2014

3. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro);G von Minckwitz;Ann Oncol,2014

4. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31;EA Perez;J Clin Oncol,2011

5. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study;N Maass;J Cancer Res Clin Oncol,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis;BMC Cancer;2024-04-09

2. Preclinical and Clinical Trials of New Treatment Strategies Targeting Cancer Stem Cells in Subtypes of Breast Cancer;Cells;2023-02-24

3. Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis;Clinical and Experimental Medicine;2022-09-24

4. Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses;International Journal of General Medicine;2022-06

5. Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial;Cancers;2021-01-05